Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Blood
|
June 5, 2026
IRF2 is an Essential Transcription Factor with Pathogenic and Prognostic Impact in Multiple Myeloma
Nahia Gómez-Echarte, Arantxa Carrasco-Leon, Alba Maiques-Diaz, et al.
Blood Advances
|
August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Future Oncology (London, England)
|
March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Ajay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood
|
September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Blood Advances
|
July 26, 2024
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Maria Luisa Palacios-Berraquero, Paula Rodriguez-Marquez, Maria Erendira Calleja-Cervantes, et al.
Blood
|
October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Blood
|
June 5, 2026
IRF2 is an Essential Transcription Factor with Pathogenic and Prognostic Impact in Multiple Myeloma
Nahia Gómez-Echarte, Arantxa Carrasco-Leon, Alba Maiques-Diaz, et al.
Blood Advances
|
August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Future Oncology (London, England)
|
March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Ajay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood
|
September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Blood Advances
|
July 26, 2024
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Maria Luisa Palacios-Berraquero, Paula Rodriguez-Marquez, Maria Erendira Calleja-Cervantes, et al.
Blood
|
October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Page
of 8